Prescribing information

 

       

Designed for HCPs, this resource summarises the new updated ICR recommendations, detailing how the diagnosis and management of ITP has evolved as new evidence has become available.1

KEY AREAS COVERED:

  • Therapy goals
  • Strength of supporting data for current medical treatments
  • Personalising treatment plans
  • TPO-RAs for subsequent ITP therapy

Indication

REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).2

REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.2

REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.2

Abbreviations: HCP, healthcare professional; HCV, hepatitis C virus; ICR, International Consensus Report; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia; TPO-RA, thrombopoietin-receptor agonist.

References     

  1. Provan D, et al. Blood Adv. 2019;3:3780–3817.
  2. REVOLADE Summary of Product Characteristics.

Download

HCP20-C046b September 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7819/smpc

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]